Silence Therapeutics (United States)

Recent papers from Silence Therapeutics (United States)

1. A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese ParticipantsJournal of Atherosclerosis and Thrombosis · 2026
2. Leveraging Drilling Automation to Scale-Up Digital Drilling in Oil & Gas in One of the Industry's Largest Projects2025
3. Fracturing Bottomhole Pressure Comparative Study: Automated Data-Driven Algorithm vs. Downhole Gauge vs. Manual Calibration2025
4. Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumorsJournal for ImmunoTherapy of Cancer · 2024
5. A digital approach to asthma self-management in adults: Protocol for a pragmatic randomized controlled trialContemporary Clinical Trials · 2022
6. Biomarkers for drug development in propionic and methylmalonic acidemiasJournal of Inherited Metabolic Disease · 2022
7. Immunogenicity of Antibody–drug Conjugates: Observations Across 8 Molecules in 11 Clinical TrialsBioanalysis · 2019
8. Narcolepsy risk loci are enriched in immune cells and suggest autoimmune modulation of the T cell receptor repertoire2018
9. Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 ⁺ T Cells in Type 1 DiabetesScience Translational Medicine · 2013
10. Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled TrialCirculation · 2009
11. Improved Efficacy of a Tolerizing DNA Vaccine for Reversal of Hyperglycemia through Enhancement of Gene Expression and Localization to Intracellular SitesThe Journal of Immunology · 2008
12. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardiumBritish Journal of Pharmacology · 2007
13. Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy SubjectsThe Journal of Clinical Pharmacology · 2006
14. Tonic activity of the rat adipocyte A₁‐adenosine receptorBritish Journal of Pharmacology · 2002
15. Observations of neutral atoms from the solar windJournal of Geophysical Research Atmospheres · 2001
16. Differential A₁‐adenosine receptor reserve for inhibition of cyclic AMP accumulation and G‐protein activation in DDT₁ MF‐2 cellsBritish Journal of Pharmacology · 2000
17. Role of A2A‐adenosine receptor activation for ATP‐mediated coronary vasodilation in guinea‐pig isolated heartBritish Journal of Pharmacology · 2000
18. A comparison of an A₁ adenosine receptor agonist (CVT‐510) with diltiazem for slowing of AV nodal conduction in guinea‐pigBritish Journal of Pharmacology · 1999
19. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo.Journal of Clinical Investigation · 1996
20. Relaxin Binds to and Elicits a Response from Cells of the Human Monocytic Cell Line, THP-1Journal of Biological Chemistry · 1996